Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in oncology, today announced the dosing of the first patient in ...

Acerand Therapeutics Initiates First-in-Human Phase I Clinical Trial of ACE-232, a Novel CYP11A1 Inhibitor for Advanced Prostate Cancer Acerand Therapeutics, a clinical-stage biotech company focusing ...

SHANGHAI & INDIANAPOLIS, June 05, 2025--(BUSINESS WIRE)--Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in ...

Haisco Pharmaceutical Group Co. Ltd. has divulged cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of cancer.

Xuanzhu Pharma Co. Ltd. has divulged cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of castration-resistant prostate cancer.

Orion has been granted a patent for compounds that inhibit cytochrome P450 monooxygenase 11A1 (CYP11A1), potentially useful in treating androgen receptor-dependent conditions, including prostate ...

OBJECTIVE: The objective of this study was to investigate the allele frequencies of polymorphisms in genes CYP11A1 rs4886595 and CYP11A1 rs4887139 that are responsible for the steroidogenesis ...

MK-5684/ODM-208 is a selective CYP11A1 inhibitor currently under investigation in the phase 3 OMAHA1 and OMAHA2a trials. Orion Corporation and Merck have mutually agreed to exercise an option that ...